Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

by divibasicbldev | Jan 13, 2026 | Press Releases

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the...

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

by divibasicbldev | Dec 2, 2025 | Press Releases

Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI,...

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

by divibasicbldev | Nov 28, 2025 | Press Releases

Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) —...

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

by divibasicbldev | Nov 25, 2025 | Press Releases

— The ALS Association is the world’s leading funder of amyotrophic lateral sclerosis (ALS) research — — The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven clinical trials of novel or...

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

by divibasicbldev | Nov 24, 2025 | Press Releases

— Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – –Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved exposures (AUC) of 6,690...

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

by divibasicbldev | Nov 21, 2025 | Press Releases

— Tablet PK exposure increases proportionally with an increase in dose — — More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability...